Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Synairgen (SNG)

Price 4.555p on 22-10-2024 at 16:30:00
Change -0.25p -5.2%
Buy 5.00p
Sell 4.11p
Buy / Sell SNG Shares
Last Trade: Sell 25,000.00 at 4.50p
Day's Volume: 146,109
Last Close: 4.555p
Open: 4.805p
ISIN: GB00B0381Z20
Day's Range 0.00p - 0.00p
52wk Range: 3.00p - 10.62p
Market Capitalisation: £10m
VWAP: 4.598052p
Shares in Issue: 201m

Recent Trades History Synairgen (SNG)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 25,000 4.50p Ordinary
16:26:15 - 22-Oct-24
Sell* 2,900 4.30p Ordinary
16:14:26 - 22-Oct-24
Sell* 1,059 4.30p Ordinary
14:16:38 - 22-Oct-24
Buy* 60 5.00p Ordinary
13:27:36 - 22-Oct-24
Sell* 1,745 4.30p Ordinary
12:23:09 - 22-Oct-24
Buy* 2,000 5.00p Ordinary
11:23:10 - 22-Oct-24
Buy* 107,449 4.6478p Ordinary
10:12:51 - 22-Oct-24
Sell* 4,902 4.199p Ordinary
09:25:58 - 22-Oct-24
Buy* 232 4.6478p Ordinary
09:20:24 - 22-Oct-24
Sell* 257 4.199p Ordinary
09:20:23 - 22-Oct-24

Share Price History for Synairgen

Time period:
to
Date Open High Low Close Volume

Share News for Synairgen

UK shareholder meetings calendar - next 7 days

3rd Oct 2024 15:46

Read More

EARNINGS: Hansard Global profit down; Flowtech cuts outlook

26th Sep 2024 19:33

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Synairgen slashes costs and focuses on small hospital trials

27th Jun 2024 12:04

Synairgen PLC - South Hampton, England-based drug discovery and development company focused on combatting respiratory disease - In 2023, pretax loss narrowed to GBP9.7 million from GBP20.1 million a year prior. No revenue generated. Research & Development expenditure down 56% to GBP6.5 million from GBP14.9 million. Other administrative expenses fell 30% to GBP3.8 million from GBP5.4 million. Cash and cash equivalents held at GBP10.5 million, down 34% from GBP15,9 million. Read More

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

7th May 2024 09:51

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday: Read More

IN BRIEF: Synairgen names Phytome's Joseph Colliver as CFO

11th Oct 2023 11:19

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Appoints Joseph Colliver as chief financial officer with effect from November 6. Current CFO John Ward will step down from his role on November 3. Colliver has previously held CFO and senior commercial roles at Sativa Group Inc, and within the Kantar division of WPP PLC. He is currently CFO at Phytome Life Sciences Ltd, a pharmaceutical manufacturing firm focused on plant-based medicines. Read More

FTSE 100 Latest
Value8,306.54
Change-11.70

Login to your account

Forgot Password?

Not Registered